Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Certain countries as Paraguay, 7,274,164 ppl only require a very small 934 ppl P3 immunobridging for EUA, in which a vaccine's effectiveness is inferred through a comparison of neutralizing antibodies generated rather than actual clinical results in the field. Ino could do the same to expedite the EUA. CD4+, CD8+ T cell responses should also be the important metrics.

The 40K ppl WHO’s Solidarity Vaccine Trial is a head-2-head comparison, also measures Percentage of Participants, (SARS-CoV-2 seronegative at baseline), With Virologically-confirmed COVID-19 Disease [ Time Frame: From 14 days after completion of the 2-dose regimen up to 12 months post-dose 2].